Affimed N.V. AFMDQ

AFMDQ Company Overview

Affimed N.V. is a clinical-stage immuno-oncology company focused on developing innate immune cell engagers designed to harness the body’s natural killer (NK) cells and T cells to treat cancer. The company operates within the biotechnology and pharmaceutical industries, with a primary focus on hematologic malignancies and selected solid tumors. Affimed’s core technology platform centers on its proprietary ROCK® (Redirected Optimized Cell Killing) platform, which is designed to generate tetravalent bispecific antibody therapeutics that activate immune cells against cancer targets.

The company’s primary value drivers have historically included its lead clinical candidates, strategic collaborations, and intellectual property related to innate immune engagement technologies. Key programs have included AFM13, targeting CD30-positive malignancies, and additional ICE® (Innate Cell Engager) candidates directed toward EGFR and other tumor-associated antigens. Affimed was founded in Germany in 2000 and later established a corporate presence in the Netherlands as Affimed N.V., while maintaining substantial research and operational activities in Europe and the United States. The company evolved from an early-stage antibody engineering business into a clinical-stage oncology developer through internal platform development, licensing, and strategic partnerships.